Navigation Links
Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes
Date:5/26/2011

known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. You should understand that these statements are not guarantees of performance or results and are preliminary in nature. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.

You should consider the areas of risk described under the heading "Forward-Looking Statements" and "Risk Factors" in Endo's periodic reports filed with the Securities and Exchange Commission under the Exchange Act and those risk factors included as "Item 1A. Risk Factors" in Endo's Annual Report on Form 10-K for the year ended December 31, 2010, as updated by the risk factors set forth in any subsequent filing by Endo with the Securities and Exchange Commission, in connection with any forward-looking statements that may be made by Endo generally. Except for ongoing obligations to disclose material information under the federal securities laws, Endo undertakes no obligation to release publicly any updates or revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events unless required by law.


'/>"/>
SOURCE Endo Pharmaceuticals Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Reductions in kidney ... years in people with diabetes type 2 ... benefits for the kidneys." Australian researchers have ... 2 diabetes leads to persistent reductions in kidney failure ... The global study has found that, five and a ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... , Sept. 18, 2014  Aratana Therapeutics, ... therapeutics company focused on licensing, developing and commercializing ... the full exercise of the underwriters, option to ... connection with the company,s previously announced public offering ... the shares are being offered by Aratana Therapeutics.  ...
Breaking Medicine Technology:ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... Response or Reduction of,Lesion Size by More than ... 2007 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation today announced the ... the safety and,efficacy of pilot process HspE7, an ... women,with the highest grade of cervical dysplasia (CIN ...
... WIRE)--Mar 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel's ... from trials of BL-1040 demonstrating that,BL-1040 is ... a myocardial infarction (MI), thereby reducing left ... pig model. Professor,Jonathan Leor, MD, Director of ...
Cached Medicine Technology:Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 2Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 3Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 4Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 5Nventa Announces Presentation of Positive HspE7 Data from,NCI-Sponsored Clinical Trial in Cervical Dysplasia 6BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
(Date:9/19/2014)... Research & Road Safety - Queensland (CARRS-Q) study have ... (OSIT) which is being held on the Gold Coast ... road safety researcher, said speed limit credibility was being ... traffic controls remained in place at inactive roadwork sites. ... asked to slow down at roadwork sites but find ...
(Date:9/19/2014)... researchers showed monkeys a number of images representing ... of 39 neurons by using microelectrodes. They found ... intensities of the responses linearly according to either ... This shows that these 3 perceptual parameters are ... variety of glosses. They also found that different ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development firm, has ... Xaverian Brothers. The new site aligns the Catholic order of ... another through a life of Gospel witness lived in community ... care and compassionate love to the people of the world ... responsive web design, which allows users to easily access information ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... Wonder tickets for his 2014 concert tour. Concertgoers ... the music business, there are a handful of artists that ... Wonder. Born in Saginaw, MichIgan, Wonder has been a force ... his time in the music business, he has released 23 ...
(Date:9/19/2014)... September 19, 2014 Lifeinsuranceover50s.biz as released ... who have heart disorders can still qualify for life ... qualify for life insurance plans that do not require ... be purchased online, in just a few minutes. ... also be purchased by clients who have health problems, ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:Neurons express 'gloss' using three perceptual parameters 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... bitten by a bat and subsequently diagnosed with rabies has been ... is being offered, the chances of the boy recovering is very ... of Humble High School fell ill last week, unaware of the ... could happen, a bat had flown into his house while he ...
... study conducted by a team at Queeen's has suggested ... when hooked up to dialysis// yield better results in ... ,This five-month, exercise intervention study of dialysis patients ... King-VanVlack, member of the Cardiac, Circulation and Respiratory (CCR) ...
... that more than 80 million American adults are smokers, obese or ... and an early death. // ,Data from a ... of adults in the United States who have one or both ... categories is about 9 million people and this would include a ...
... study states that the organ donation rate in UK is ... relatives are reluctant to allow such procedures. // This was ... potential organ donors because they are distressed and confused about ... ,The UK Transplant, which carried out a two-year audit, ...
... the Japanese Encephalitis immunization drive has not gone down well ... have taken place on June 18, but the government has ... delivery of 5.2 million doses of the Japanese Encephalitis tissue ... , ,The remaining 13.5 million doses are expected to ...
... to place on record the exemplary work of art by students ... effort by Oman in the ‘Unite for children Unite against Aids’ ... ‘Unite for Children Unite Against Aids’ campaign encompasses four major goals ... the percentage of the young victims of HIV/Aids; to provide better ...
Cached Medicine News:Health News:Exercise Combined with Dialysis Yields Better Results 2Health News:Grieving Relatives Reluctant To Give Consent For Organ Donation 2
Nitinol Flat Wire Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: